Pfizer Inc. $PFE Shares Acquired by Swedbank AB

Posted by Brian Himes on May 24th, 2026

Swedbank AB lifted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,490,272 shares of the biopharmaceutical company’s stock after purchasing an additional 627,384 shares during the period. Swedbank AB’s holdings in Pfizer were worth $136,708,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Triad Wealth Partners LLC increased its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. increased its position in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its position in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC increased its position in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC increased its position in shares of Pfizer by 0.9% during the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 403 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wolfe Research reiterated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.61.

Check Out Our Latest Stock Report on Pfizer

Pfizer Stock Performance

Shares of PFE stock opened at $25.92 on Friday. The stock has a market capitalization of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 52-week low of $22.88 and a 52-week high of $28.75. The stock’s 50-day moving average price is $26.86 and its 200 day moving average price is $26.23. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.